Researcher:
Akyol, Merve

Profile Picture
ORCID

Job Title

Undergraduate Student

First Name

Merve

Last Name

Akyol

Name

Name Variants

Akyol, Merve

Email Address

Birth Date

Filters

2020 - 20224

Advanced Search

Filter by

Settings

Researcher Of Publications: search.filters.isAuthorOfPublication.309eda52-c0ee-4fdf-a112-0e4fed87d307

Search Results

Now showing 1 - 5 of 5
  • Placeholder
    PublicationMetadata only
    Potential use of SGLT-2 inhibitors in obstructive sleep apnea: a new treatment on the horizon
    (Springer Heidelberg) Kanbay, Asiye; Sridhar, Vikas S.; Cherney, David Z., I; Tanrıöver, Cem; Uçku, Duygu; Akyol, Merve; Çevik, Enes; Kanbay, Mehmet; Undergraduate Student; Undergraduate Student; Undergraduate Student; Undergraduate Student; Faculty Member; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; N/A; N/A; N/A; N/A; 110580
    Background: Obstructive sleep apnea (OSA) is characterized by hypoxic episodes due to collapse of the airway during sleep and is frequently associated with obesity, type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVD). There is currently no pharmacological agent approved for the treatment of OSA. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have the potential to both increase life expectancy and quality of life of these patients making them promising agents for this role. There are relatively few studies investigating this possible beneficial relationship between these drugs and OSA. Method: We aimed to increase awareness on the potential benefits of SGLT2 inhibitors in OSA patients by describing the current evidence on the effectiveness of these inhibitors in both overall and cardiovascular morbidity and mortality. We performed a literature search for articles reporting on the use of SGLT2 inhibitors in patients with OSA and T2DM. Results: We identified 4 manuscripts studying the use of SGLT2 inhibitors in 475 OSA patients with T2DM. Among them, 332 patients were administered SGLT2 inhibitors, and 143 patients were in a control group. SGLT2 inhibitors have many potential positive impacts on OSA patients by targeting various mechanisms involved in OSA pathogenesis. Conclusion: SGLT2 inhibitors are prime pharmacological candidates for the treatment of OSA, and additional studies are needed to better explore mechanisms and outcomes unique to this population. Additionally, patients with OSA often have multiple comorbidities that are clinical indications for SGLT2 inhibitor therapy. Physicians should recognize and encourage the use of these agents in such patients.
  • Placeholder
    PublicationMetadata only
    A meta-analysis for the role of aminoglycosides and tigecyclines in combined regimens against colistin- and carbapenem-resistant Klebsiella pneumoniae bloodstream infections
    (Springer, 2022) N/A; N/A; N/A; N/A; N/A; N/A; N/A; N/A; N/A; Department of Industrial Engineering; N/A; Demirlenk, Yusuf Mert; Gücer, Lal Sude; Uçku, Duygu; Tanrıöver, Cem; Akyol, Merve; Kalay, Zeynepgül; Barçın, Erinç; Akcan, Rüştü Emre; Can, Füsun; Gönen, Mehmet; Ergönül, Önder; Undergraduate Student; Researcher; Researcher; Undergraduate Student; Undergraduate Student; Undergraduate Student; Master Student; N/A; Undergraduate Student; Faculty Member; Faculty Member; Faculty Member; Department of Industrial Engineering; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; Graduate School of Health Sciences; School of Medicine; School of Medicine; School of Medicine; College of Engineering; School of Medicine; N/A; 375775; N/A; N/A; N/A; N/A; N/A; N/A; N/A 237468; 110398
    We aimed to describe the effect of aminoglycosides and tigecycline to reduce the mortality in colistin- and carbapenem-resistant Klebsiella pneumoniae (ColR-CR-Kp) infections. We included the studies with defined outcomes after active or non-active antibiotic treatment of ColR-CR-Kp infections. The active treatment was defined as adequate antibiotic use for at least 3 days (72 h) after the diagnosis of ColR-CR-Kp infection by culture. The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement and the checklist of PRISMA 2020 was applied. Crude and adjusted odds ratios (OR) with 95% confidence interval (CI) were calculated and pooled in the random effects model. Adding aminoglycosides to the existing treatment regimen reduced overall mortality significantly (OR 0.34, 95% CI 0.20-0.58). Overall mortality was 34% in patients treated with aminoglycoside-combined regimens and was 60% in patients treated with non-aminoglycoside regimens. Treatment with tigecycline is not found to reduce mortality (OR: 0.76, 95% CI: 0.47-1.23). Our results suggest that aminoglycoside addition to the existing regimen of colistin- and carbapenem-resistant Klebsiella pneumoniae infections reduces mortality significantly.
  • Thumbnail Image
    PublicationOpen Access
    Immunogenicity of SARS-CoV-2 mRNA vaccine in dialysis and kidney transplant patients: a systematic review
    (Bilimsel Tıp Yayınevi, 2021) Afşar, Barış; Kanbay, Asiye; Covic, Adrian; Ortiz, Alberto; Basile, Carlo; Akyol, Merve; Çevik, Enes; Uçku, Duygu; Tanrıöver, Cem; Kanbay, Mehmet; Undergraduate Student; Faculty Member; School of Medicine; N/A; N/A; N/A; N/A; 110580
    Kidney transplant recipients and dialysis patients constitute a risk group for severe COVID-19. They are highly advised to get vaccinated according to the current guidelines. However, data on antibody response, cell responses and protection from events, and factors that might alter this response after a rou-tine full series of vaccination remain incomplete for these populations. The aim of this article was to analyze the antibody responses after a full series of mRNA-based SARS-CoV-2 vaccination in kidney transplantation and dialysis patients and to define the factors that alter seroconver-sion status in these populations. In this systematic review, 18 studies investigating the antibody response to full vaccination with two doses of COVID-19 mRNA vaccines in hemodialysis, peritoneal dialysis, and kidney transplant patients were included. Kidney transplant and dialysis patients have a lower seroconversion rate after mRNA-based SARS-CoV-2 vaccination than the healthy population: 27.2% for kidney transplantation, 88.5% for dialysis patients while all healthy control in these studies seroconverted. Moreover, anti-S antibody titers were lower in seroconverted kidney transplantation or dialysis patients than in healthy control in all studies that assessed this variable. Older age and dialysis vintage, immunosuppressive or chemotherapy treatment, and lower serum albumin, white blood cell, lymphocyte and hemoglobin counts were associated with lower/no antibody response to vaccination. Dialysis patients and kidney transplant recipients have lower seroconversion rates after a full series of mRNA-based SARS-CoV-2 vaccination than the general population. Several factors are associated with an altered antibody response. A third dose could be considered in this patient group / Böbrek nakilli ve diyaliz hastaları COVID-19 enfeksiyonu açısından yüksek riskli gruptadırlar. Güncel klavuzlar bu nedenle bu hastaların öncelikli aşılanması gereken grupta olduğunu belirtmişlerdir. Bununla birlikte aşı sonrası antikor yanıt, koruyuculuğu, hücresel immün yanıt üzerine etkileri net olarak bilinmemektedir. Bu sistematik derlemede mRNA-tipi SARS-CoV-2 aşılamanın böbrek nakli ve diyaliz hastalarında antikor yanıtını ve antikor yanıtını etkileyen faktörlerin araştırılması yapıldı. Bu sistematik derlemeye 18 adet hemodiyaliz, periton diyaliz ve böbrek nakli hastalarında 2 doz COVID-19 mRNA aşısı uygulanan hastaların alındığı klinik çalışma dahil edildi. Çalışmalarda 2 doz COVID-19 mRNA aşısı sonrası böbrek nakli hastalarında %27,2, diyaliz hastalarında %88,5 antikor yanıtı saptanırken sağlıklı insanlarda %100 antikor yanıtı saptandı. İleri yaş, diyaliz süresi, immünsüpresif tedavi, düşük serum albumin, düşük serum lökosit, düşük serum lenfosit, düşük hemoglobin düzeyleri düşük antikor yanıtı ile ilişkili olduğu saptandı. COVID19 mRNA aşısı sonrası diyaliz ve böbrek nakli hastalarında antikor yanıtı düşüktür. Bu nedenle bu hasta grubunda üçüncü doz aşı uygulanması uygun olabilir
  • Thumbnail Image
    PublicationOpen Access
    National case fatality rates of the COVID-19 pandemic
    (Elsevier, 2020) Tiemeier, H. W.; Petersen, Eskild; Petrosillo, Nicola; Department of Industrial Engineering; Ergönül, Önder; Akyol, Merve; Tanrıöver, Cem; Gönen, Mehmet; Faculty Member; Undergraduate Student; Faculty Member; Department of Industrial Engineering; School of Medicine; College of Engineering; 110398; N/A; N/A; 237468
    Objectives: the case fatality rate (CFR) of coronavirus disease 2019 (COVID-19) varies significantly between countries. We aimed to describe the associations between health indicators and the national CFRs of COVID-19. Methods: we identified for each country health indicators potentially associated with the national CFRs of COVID-19. We extracted data for 18 variables from international administrative data sources for 34 member countries of the Organization for Economic Cooperation and Development (OECD). We excluded the collinear variables and examined the 16 variables in multivariable analysis. A dynamic web-based model was developed to analyse and display the associations for the CFRs of COVID-19. We followed the Guideline for Accurate and Transparent Health Estimates Reporting (GATHER). Results: in multivariable analysis, the variables significantly associated with the increased CFRs were percentage of obesity in ages >18 years (β = 3.26; 95%CI = 1.20, 5.33; p 0.003), tuberculosis incidence (β = 3.15; 95%CI = 1.09, 5.22; p 0.004), duration (days) since first death due to COVID-19 (β = 2.89; 95%CI = 0.83, 4.96; p 0.008), and median age (β = 2.83; 95%CI = 0.76, 4.89; p 0.009). The COVID-19 test rate (β = –3.54; 95%CI = –5.60, –1.47; p 0.002), hospital bed density (β = –2.47; 95%CI = –4.54, –0.41; p 0.021), and rural population ratio (β = –2.19; 95%CI = –4.25, –0.13; p 0.039) decreased the CFR. Conclusions: the pandemic hits population-dense cities. Available hospital beds should be increased. Test capacity should be increased to enable more effective diagnostic tests. Older patients and patients with obesity and their caregivers should be warned about a potentially increased risk.
  • Thumbnail Image
    PublicationOpen Access
    SLUG-related partial epithelial-to-mesenchymal transition is a transcriptomic prognosticator of head and neck cancer survival
    (Wiley, 2021) Schinke, Henrik; Pan, Min; Zhou, Jiefu; Shi, Enxian; Kranz, Gisela; Libl, Darko; Quadt, Tanja; Simon, Florian; Canis, Martin; Baumeister, Philipp; Gires, Olivier; Akyol, Merve; School of Medicine
    Partial epithelial-to-mesenchymal transition (pEMT) contributes to cellular heterogeneity that is associated with nodal metastases and unfavorable clinical parameters in head and neck squamous cell carcinomas (HNSCCs). We developed a single-cell RNA sequencing signature-based pEMT quantification through cell type-dependent deconvolution of bulk RNA sequencing and microarray data combined with single-sample scoring of molecular phenotypes (Singscoring). Clinical pEMT-Singscores served as molecular classifiers in multivariable Cox proportional hazard models and high scores prognosticated poor overall survival and reduced response to irradiation as independent parameters in large HNSCC cohorts [The Cancer Genome Atlas (TCGA), MD Anderson Cancer Centre (MDACC), Fred Hutchinson Cancer Research Center (FHCRC)]. Differentially expressed genes confirmed enhanced cell motility and reduced oxidative phosphorylation and epithelial differentiation in pEMT(high) patients. In patients and cell lines, the EMT transcription factor SLUG correlated most strongly with pEMT-Singscores and promoted pEMT, enhanced invasion, and resistance to irradiation in vitro. SLUG protein levels in HNSCC predicted disease-free survival, and its peripheral expression at the interphase to the tumor microenvironment was significantly increased in relapsing patients. Hence, pEMT-Singscores represent a novel risk predictor for HNSCC stratification regarding clinical outcome and therapy response that is partly controlled by SLUG.